Han-Byoel Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Han-Byoel Lee has a total of 392 co-authors. Here are the top co-authors by number of shared publications:
- Wonshik Han
Division of Breast Surgery, Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
108 shared publications - Hee-Chul Shin
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
56 shared publications - Hye-Mi Choi
DCGen, Co., Ltd., Seoul, Republic of Korea
55 shared publications - Jihye Choi
Department of General Surgery, National Medical Center, Seoul, Republic of Korea
55 shared publications - Tae-Woong Ha
DCGen, Co., Ltd., Seoul, Republic of Korea
55 shared publications - Woosung Chung
DCGen Co. Ltd., Seoul, Korea
55 shared publications
Latest Publications
- 26 August 2026
- Published by Taylor & Francis in Chronobiology International
- p. 1-11
Earlier bedtime misalignment is associated with increased severity of chemotherapy-induced hot flashes in premenopausal women with breast cancer
Breast cancer is the most common malignancy among women, and survival rates have markedly improved with advances in early detection and treatment modalities (Amato et al. 2023; Bray et al. 2024). C...
- 26 August 2026
- Published by Taylor & Francis in Chronobiology International
- p. 1-11
Earlier bedtime misalignment is associated with increased severity of chemotherapy-induced hot flashes in premenopausal women with breast cancer
Breast cancer is the most common malignancy among women, and survival rates have markedly improved with advances in early detection and treatment modalities (Amato et al. 2023; Bray et al. 2024). C...
- 20 July 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (10)
Revisiting OPTIMIST trial imaging criteria for pathologic complete response to neoadjuvant therapy
- 20 July 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (10)
Revisiting OPTIMIST trial imaging criteria for pathologic complete response to neoadjuvant therapy
- Open Access
- 14 February 2026
- Published by Elsevier in The Breast
- Vol. 86, 104738
Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study
- 14 February 2026
- Published by Elsevier in The Breast
- Vol. 86, 104738
Open AccessLate distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study
- 3 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111458
Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21
- 3 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111458
Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (4) , 389-394
Differential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer
Koh JH, et al. J Breast Cancer. 2026 Aug;29(4):389-394. https://doi.org/10.4048/jbc.2025.0109
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (4) , 389-394
Open AccessDifferential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer
Koh JH, et al. J Breast Cancer. 2026 Aug;29(4):389-394. https://doi.org/10.4048/jbc.2025.0109
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (2) , 154-162
Clinical Implications of the Langer’s Axillary Arch Muscle in Breast Cancer Patients
Kang E, et al. J Breast Cancer. 2026 ;29:e16. https://doi.org/10.4048/jbc.2025.0264
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (2) , 154-162
Open AccessClinical Implications of the Langer’s Axillary Arch Muscle in Breast Cancer Patients
Kang E, et al. J Breast Cancer. 2026 ;29:e16. https://doi.org/10.4048/jbc.2025.0264
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (1) , 81-89
Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)
Ahn SG, et al. J Breast Cancer. 2026 Jan;29:e4. https://doi.org/10.4048/jbc.2025.0181
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (1) , 81-89
Open AccessProspective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)
Ahn SG, et al. J Breast Cancer. 2026 Jan;29:e4. https://doi.org/10.4048/jbc.2025.0181
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figures from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling
Supplementary Table 1. Information about patients derived xenograft models and derived patient.Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models.Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models.Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing.Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 7. Demographic and clinical characteristics of all patients.Supplementary Table 8. Information about used primer sequences for quantitative real-time PCRSupplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model's liver (left) and lung (right) taken at 400x magnification.Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients.Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining.Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice.Supplementary Figure 5. Identification of CX3CR1 positive cell population.Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines.Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1.Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models.Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment.Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages.Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases.Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR.Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models.Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figures from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling
Supplementary Table 1. Information about patients derived xenograft models and derived patient.Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models.Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models.Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing.Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 7. Demographic and clinical characteristics of all patients.Supplementary Table 8. Information about used primer sequences for quantitative real-time PCRSupplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model's liver (left) and lung (right) taken at 400x magnification.Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients.Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining.Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice.Supplementary Figure 5. Identification of CX3CR1 positive cell population.Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines.Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1.Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models.Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment.Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages.Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases.Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR.Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models.Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling
Patients with triple-negative breast cancer (TNBC) often develop metastases in visceral organs including the liver, but the detailed molecular mechanisms of TNBC liver metastasis is not clearly understood. In this study, we tried to dissect the process of premetastatic niche formation in the liver by using patient-derived xenograft (PDX) models of TNBC with different metastatic propensity. RNA sequencing of TNBC PDX models that successfully metastasized to liver showed upregulation of the Cx3cr1 gene in the liver microenvironment. In syngeneic breast cancer models, the Cx3cr1 upregulation in liver preceded the development of cancer cell metastasis and was the result of recruitment of CX3CR1-expressing macrophages. The recruitment was induced by the CX3CL1 production from the liver endothelial cells and this CX3CL1–CX3CR1 signaling in the premetastatic niche resulted in upregulation of MMP9 that promoted macrophage migration and cancer cell invasion. In addition, our data suggest that the extracellular vesicles derived from the breast cancer cells induced the TNFα expression in liver, which leads to the CX3CL1 upregulation. Lastly, the plasma CX3CL1 levels in 155 patients with breast cancer were significantly associated with development of liver metastasis.Implications:Our data provides previously unknown cascades regarding the molecular education of premetastatic niche in liver for TNBC.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling
Patients with triple-negative breast cancer (TNBC) often develop metastases in visceral organs including the liver, but the detailed molecular mechanisms of TNBC liver metastasis is not clearly understood. In this study, we tried to dissect the process of premetastatic niche formation in the liver by using patient-derived xenograft (PDX) models of TNBC with different metastatic propensity. RNA sequencing of TNBC PDX models that successfully metastasized to liver showed upregulation of the Cx3cr1 gene in the liver microenvironment. In syngeneic breast cancer models, the Cx3cr1 upregulation in liver preceded the development of cancer cell metastasis and was the result of recruitment of CX3CR1-expressing macrophages. The recruitment was induced by the CX3CL1 production from the liver endothelial cells and this CX3CL1–CX3CR1 signaling in the premetastatic niche resulted in upregulation of MMP9 that promoted macrophage migration and cancer cell invasion. In addition, our data suggest that the extracellular vesicles derived from the breast cancer cells induced the TNFα expression in liver, which leads to the CX3CL1 upregulation. Lastly, the plasma CX3CL1 levels in 155 patients with breast cancer were significantly associated with development of liver metastasis.Implications:Our data provides previously unknown cascades regarding the molecular education of premetastatic niche in liver for TNBC.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Development of a Breast Cancer Risk Prediction Model Incorporating Polygenic Risk Scores and Nongenetic Risk Factors for Korean Women
The absolute risk was estimated using different combinations of PRS and NGRF risk levels. PRS was classified into three risk groups according to percentile distributions (0-20%: low, 20-80%: mid, 80-100%: high). NGRF score was classified into two groups divided at median (0-50%: low, 50-100%: high). The dotted lines represent the average risks. (A) Lifetime absolute risk (B) 5-year absolute risk
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Development of a Breast Cancer Risk Prediction Model Incorporating Polygenic Risk Scores and Nongenetic Risk Factors for Korean Women
The absolute risk was estimated using different combinations of PRS and NGRF risk levels. PRS was classified into three risk groups according to percentile distributions (0-20%: low, 20-80%: mid, 80-100%: high). NGRF score was classified into two groups divided at median (0-50%: low, 50-100%: high). The dotted lines represent the average risks. (A) Lifetime absolute risk (B) 5-year absolute risk